AKT1 and type 2 diabetes mellitus: In an experiment using a mice model of T2D-AD conducted in 2023, empagliflozin was reported to reduce p-Tau levels by activating ACE2/MasR that might crosstalk with IRS1/AKT/GSK3β pathways [86].